Danvilostomig is under clinical development by Systimmune and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Danvilostomig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Danvilostomig overview
Danvilostomig (SIB-003) is under development for the treatment of solid tumors including metastatic solid tumors including colorectal cancer, human epidermal growth factor receptor 2 negative breast cancer, melanoma, recurrent head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial cancer, triple-negative breast cancer, cervical cancer, head and neck squamous cell carcinoma, oral cavity cancer, small-cell lung cancer, endometrial cancer, fallopian tube cancer, peritoneal cancer, epithelial ovarian cancer, vulvar cancer, vaginal cancer, nasopharyngeal cancer and primary sarcoma of the gynecological reproductive system, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, esophageal cancer, gastrointestinal tumor and advanced renal cell carcinoma. The drug candidate is a bi-specific antibody acts by targeting two check point inhibitors of EGFR family. It is developed based on bi-specific engineering SEBA platform. It is administered through intravenous route. It was also under development for the treatment of lung cancer, kidney cancer and glioblastoma multiforme. It acts by targeting programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4).
Systimmune overview
Systimmune, a subsidiary of Sichuan Biokin Pharmaceutical Co Ltd, is a biopharmaceutical company. It utilizes specificity-enhanced bi-specific antibody (SEBA), guidance and navigation control (GNC) and HIRE-ADC platforms to develop novel therapeutic bi-specific, multi-specific antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The company’s pipeline products include SI-B001, SI-B003, BL-B01D1, BL-M07D1 and BL-M02D1 target solid tumors; GNC-038, GNC-035 and GNC-039 treats lymphoma, leukemia, solid tumors and glioblastoma; and BL-M11D1 and BL-M05D1 are monospecific antibodies for R/R AML (acute myeloid leukemia) and gastric cancer. Systimmune is headquartered in Redmond, Washington, the US.
For a complete picture of Danvilostomig’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
